Targets › TRB
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2027.
The beta chain of TRAV27*01J42*01C*01/TRBV19*01J2S7*01C*02 alpha-beta T cell receptor (TR) clonotype that is specific for HLA-A*02:01-restricted M/matrix protein 1 immunodominant epitope GILGFVFTL of influenza A virus (IAV). Classified as a public TCR clonotype, it is preferentially selected in effector memory CD8-positive T cells among multiple HLA-A*02:01 carriers/individuals and confers long-lived immunity…. (UniProt, P0DSE2)
Open in Phaseline: the race on TRB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jonsson Comprehensive Cancer Center | NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL T cell receptor (TCR) gene-engineered lymphocytes targeting NY-ESO-1 antigen | TRA, TRB | Phase 2 | Malignant Neoplasm | Nov 2027 |
| University of Chicago | NY-ESO-1 TCR/ dnTGFβRII Gene-modified T cells expressing NY-ESO-1-specific T cell receptor and dominant-negative T | TRA, TRB, TGFBR2 | Phase 1 | Ovarian Cancer | Dec 2031 |
Ovarian Cancer (1) Malignant Neoplasm (1)
mixed (2)
University of Chicago (1) Jonsson Comprehensive Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.